VX-840 / Vertex - LARVOL DELTA

A Phase 1 Dose Escalation Study to Evaluate Safety and Pharmacokinetics (PK) of VX-840 in Healthy Participants (clinicaltrials.gov) - P1 | N=88 | Completed | Sponsor: Vertex Pharmaceuticals Incorporated | Recruiting ➔ Completed

Trial completion • Nephrology • Renal Disease